Cianidanol

Cianidanol

SCHEMBL5081456

Oc1cc(O)c2c(c1)O[C@H](c1ccc(O)c(O)c1)C(O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 1.00
KDM4E B2RXH2 6/20 1.00
HSD17B10 Q99714 5/20 1.00
SNCA P37840 5/20 1.00
ALDH1A1 P00352 4/20 1.00
MAPT P10636 4/20 1.00
PTGS1 P23219 4/20 1.00
ALOX15 P16050 4/20 1.00
GAA P10253 3/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
APEX1 P27695 3/20 1.00
RECQL P46063 3/20 1.00
CYP3A4 P08684 3/20 1.00
PKM P14618 2/20 1.00
ALPL P05186 2/20 1.00
POLB P06746 2/20 1.00
PTGS2 P35354 2/20 1.00
RAD52 P43351 2/20 1.00
HPGD P15428 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Catechin SCHEMBL10001669 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
(+)-Epicatechin SCHEMBL862089 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL1330653 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Catechin SCHEMBL10033927 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
(-)-Epicatechin SCHEMBL19412 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL12392372 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL13610161 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Catechin SCHEMBL19411 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
Cianidanol SCHEMBL19741 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1
(-)-Catechin SCHEMBL166733 1.00 BACE1 (1.00) BACE1KDM4EHSD17B10SNCAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293482-A1 CENTRAL NERVOUS SYSTEM POTENTIATING COMPOSITION SHIBAURA INSTITUTE OF TECHNOLOGY (JP) 2023-09-21 US disclosed
WO-2020054996-A1 FOAMABLE MOUTHWASH SOLID FORMULATION AND PREPARATION METHOD THEREFOR (주)주환바이오.셀 2020-03-19 WO disclosed
US-9040250-B2 Binding interaction of proanthocyanidins with bacteria and bacterial components THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2015-05-26 US disclosed
US-8715949-B2 Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2014-05-06 US disclosed
US-8501970-B2 Method for the preparation of C-4 coupled flavonoids, proanthocyanidins and analogues thereof UNIVERSITY OF THE FREE STATE (ZA) 2013-08-06 US disclosed
US-8501970-B2 Method for the preparation of C-4 coupled flavonoids, proanthocyanidins and analogues thereof UNIVERSITY OF THE FREE STATE (ZA) 2013-08-06 US disclosed
WO-2011130705-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR REDUCING OR ELIMINATING BITTER TASTE CHROMOCELL CORPORATION (US) 2011-10-20 WO disclosed
US-20110160467-A1 Method for the Preparation of C-4 Coupled Flavonoids, Proanthocyanidins and Analogues Thereof UNIVERSITY OF THE FREE STATE (ZA) 2011-06-30 US disclosed
US-20110160467-A1 Method for the Preparation of C-4 Coupled Flavonoids, Proanthocyanidins and Analogues Thereof UNIVERSITY OF THE FREE STATE (ZA) 2011-06-30 US disclosed
EP-2292226-A2 The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin MediGene AG (DE) 2011-03-09 EP disclosed
WO-2009147645-A1 METHOD FOR THE PREPARATION OF C-4 COUPLED FLAVONOIDS, PROANTHOCYANIDINS AND ANALOGUES THEREOF UNIVERSITY OF THE FREE STATE (ZA) 2009-12-10 WO disclosed
US-20080176933-A1 BINDING INTERACTION OF PROANTHOCYANIDINS WITH BACTERIA AND BACTERIAL COMPONENTS THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2008-07-24 US disclosed
EP-1355708-B1 PROCESS FOR EXTRACTING COMPOUNDS FROM PLANTS UNIV MINNESOTA (US) 2008-04-30 EP disclosed
US-20080064050-A1 APPLICATIONS OF THE BINDING INTERACTION OF PROANTHOCYANIDINS WITH BACTERIA AND BACTERIAL COMPONENTS THE GOVERNMENT OF THE US, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2008-03-13 US disclosed
US-7169763-B2 Cytochrome P450 3A inhibitors and enhancers Hu, Oliver Yoa-Pu (TW) 2007-01-30 US disclosed
US-20030166584-A1 Cytochrome P450 3A inhibitors and enhancers NATIONAL SCIENCE COUNCIL (TW) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160467-A1 Method for the Preparation of C-4 Coupled Flavonoids, Proanthocyanidins and Analogues Thereof C9, PROC, MLN BACE1 4671/4885KDM4E 543/4885HSD17B10 2586/4885
US-20230293482-A1 CENTRAL NERVOUS SYSTEM POTENTIATING COMPOSITION CHRNA7, CHRNB3, CHRNA3 BACE1 1564/4885KDM4E 4394/4885HSD17B10 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.